Nelmastobart(Nelmastobart) - 药物靶点：BTN1A1_在研适应症：头颈部肿瘤，肺癌，转移性结直肠癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Anti STT-003 Ab、Anti-butyrophilin 1A1 mAb(STCube/MD Anderson Cancer Center)、HSTC 810

+ [2]

靶点

BTN1A1

作用方式

抑制剂

作用机制

BTN1A1抑制剂(butyrophilin subfamily 1 member A1 inhibitors)

治疗领域

肿瘤呼吸系统疾病消化系统疾病

在研适应症

头颈部肿瘤肺癌转移性结直肠癌+ [2]

非在研适应症-

原研机构

STCube, Inc.

在研机构

STCube, Inc.

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 776944511H

来源: *****

Sequence Code 776944512L

来源: *****

关联

3

项与 Nelmastobart 相关的临床试验

NCT06873763

/ Recruiting临床1/2期

A Single-arm, Phase Ib/2 Study of Nelmastobart in Combination With Trifluridine/Tipiracil and Bevacizumab in Metastatic/Recurrent Colorectal Cancer Patients With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy

The objective of this multi-center, single-group, open-label Phase Ib/II study is to evaluate the safety, pharmacokinetics, and efficacy of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in metastatic or recurrent colorectal cancer patients with resistance or intolerance to oxaliplatin- and irinotecan-based chemotherapy, and to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and the efficacy and safety of the combination therapy in BTN1A1-positive patients.

开始日期2025-06-09

申办/合作机构

STCube, Inc.

NCT06016270

/ Recruiting临床1/2期

A Phase Ib/II Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and paclitaxel combination therapy in patients with relapsed or refractory extensive stage small cell lung cancer.

开始日期2024-02-13

申办/合作机构

STCube, Inc.

NCT05231746

/ Completed临床1期

A Phase 1, Multicenter, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of hSTC810 Monotherapy in Subjects With Advanced Solid Tumors

The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.

开始日期2022-04-18

申办/合作机构

STCube, Inc.

100 项与 Nelmastobart 相关的临床结果

登录后查看更多信息

100 项与 Nelmastobart 相关的转化医学

登录后查看更多信息

100 项与 Nelmastobart 相关的专利（医药）

登录后查看更多信息

100 项与 Nelmastobart 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性结直肠癌	临床2期	韩国	STCube, Inc.	2025-06-09
广泛期小细胞肺癌	临床2期	美国	STCube, Inc.	2024-02-13
头颈部肿瘤	临床2期	韩国	STCube, Inc.	-
头颈部肿瘤	临床2期	-	STCube, Inc.	-
肺癌	临床2期	韩国	STCube, Inc.	-
晚期恶性实体瘤	临床1期	美国	STCube, Inc.	2022-04-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


hSTC810 (AACR2025)	临床1期	结肠癌 BTN1A1 \| YAP1	-	hSTC810 + capecitabine	鬱廠積鬱壓構選遞膚繭(醖淵襯觸簾窪淵繭觸夢) = Treatment with hSTC810 demonstrated a favorable safety profile, with the most common adverse events being low-grade fatigue and infusion-related reactions 襯獵選淵願鬱壓壓顧蓋 (製襯淵鹽壓構醖獵鏇構 ) 更多	积极	2025-04-30
NCT05231746 (ASCO_GI2025) 人工标引	临床1期	结肠癌 BTN1A1	47	hSTC810hSTC810 monotherapy (all cohorts)	廠製壓淵繭艱鹽蓋衊齋(網範積範窪簾鬱築獵遞) = 簾餘壓蓋鑰遞鹽顧網鑰鹽鑰獵鑰鬱糧衊獵餘獵 (淵餘窪窪膚艱壓範築鑰 ) 更多	积极	2025-01-23
NCT05231746 (ASCO_GI2025) 人工标引	临床1期	结肠癌 BTN1A1	47	hSTC810hSTC810 monotherapy (CRC)	廠製壓淵繭艱鹽蓋衊齋(網範積範窪簾鬱築獵遞) = 齋積壓衊糧積鏇餘膚顧鹽鑰獵鑰鬱糧衊獵餘獵 (淵餘窪窪膚艱壓範築鑰 ) 更多	积极	2025-01-23
ASCO_GI2025	临床1期	转移性结直肠癌	12	Nelmastobart 400mg + Capecitabine 1250mg/m2	選齋淵選構鹹鏇築繭遞(鏇積廠鹹蓋壓壓壓鑰構) = 鏇範製衊繭窪蓋鹽選餘夢醖餘醖壓鹹膚鹽襯鬱 (網觸鹹積遞範觸襯艱鹽 )	积极	2025-01-23
1456 (SITC2024)	临床1期	晚期恶性实体瘤 BTN1A1 \| PD-L1	47	hSTC810 (Nelmastobart)	鹹範鏇艱壓鑰廠築選襯(蓋鹹範獵願遞獵膚選築) = showed a linear PK and consistent exposure 膚淵簾鑰壓簾憲齋願糧 (膚範積築憲窪淵艱築夢 )	积极	2024-11-05
NCT05231746 (STCUBE-001, ASCO 12023 \| ASCO 22023) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	39	STC810	餘網襯夢繭鬱築憲顧簾(糧廠遞醖夢窪襯壓艱鹽) = 糧艱淵積鏇築醖願窪簾鹹餘淵製鹹願遞獵襯選 (範築淵鹹糧範願艱鏇糧 ) 更多	积极	2023-05-26